Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AbbVie Inc presents results from study of investigational compound in Patients with Glioblastoma


Friday, 30 May 2014 08:00am EDT 

AbbVie Inc:Preliminary results from ongoing Phase I study with ABT-414, anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate.Says in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.Specifically, one patient experienced complete response (CR) and three patients experienced partial responses (PR) as measured with the Revised Assessment in Neuro-Oncology (RANO) criteria.Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor, and patients have few treatment options and a five-year survival rate of less than 3 percent.Phase I, open-label, multicenter, international trial was designed to evaluate the toxicities, pharmacokinetics and recommended Phase II dose of ABT-414 when administered every other week in combination with temozolomide in patients with recurrent or unresectable glioblastoma.Other important assessments included adverse events, pharmacokinetic parameters, objective response and tumor tissue epidermal growth factor receptor biomarkers.Later stage clinical trials are being planned to continue to investigate ABT-414 in patients with glioblastoma multiforme. 

Company Quote

59.06
-0.39 -0.66%
19 Sep 2014